Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences

OBJECTIVES: To evaluate whether the modified intraperitoneal plus intravenous chemotherapy regimen as a first-line therapy for advanced epithelial ovarian cancer (EOC) in China can be well-tolerated or confer any potential benefit on survival. METHODS: We evaluated the outcomes of women with newly d...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yuanming, Tang, Sangsang, Xu, Junfen, Xie, Xing, Chen, Zhongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968104/
https://www.ncbi.nlm.nih.gov/pubmed/35372416
http://dx.doi.org/10.3389/fmed.2022.846352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968104/
https://www.ncbi.nlm.nih.gov/pubmed/35372416
http://dx.doi.org/10.3389/fmed.2022.846352

Ejemplares similares